Researchbxcl501opioid withdrawalclinical trialbioxcel therapeutics
BioXcel Therapeutics Reports Positive Phase 2 Results For Opioid Withdrawal
3.8
Relevance Score
BioXcel Therapeutics announced positive Phase 2 topline results from a Columbia University, NIDA-funded study, reporting BXCL501 demonstrated clinical benefits and an overall favorable tolerability profile for treating opioid withdrawal symptoms.
